As of March 31, 2025, cash and cash equivalents were $2.9 million. The Company believes it has sufficient capital resources to fund its operations into late second quarter of 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- IMNN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Imunon announces first trial site initiated for Phase 3 OVATION 3 study
- Imunon announces data from Phase 1/2 OVATION 2 trial of IMNN-001
- Imunon announces IMNN-001 abstract accepted for oral presentation at 2025 ASCO
- Imunon files to sell 10M shares of common stock, warrants